| SA-L1-C2-EN-V1 | About CANTRAIN |
|
| SA-L2-C1-EN-V1 | ICH Guidance E6(R2) GCP (International Council for Harmonisation-Good Clinical Practice) |
|
| SA-L2-C2-EN-V1 | Health Canada, Part C, Division 5 of the Food and Drug Regulations |
|
| SA-L2-C3-EN-V1 | Tri-Council Policy Statement-Ethical Conduct for Research Involving Humans TCPS 2 (2022) |
|
| SA-L3-C1-EN-V1 | Study Designs and Clinical Trial Phases |
|
| SA-L3-C2-EN-V1 | Drug Discovery and Development Process |
|
| SA-L3-C3-EN-V1 | The Clinical Trial Protocol |
|
| SA-L3-C4-EN-V1 | Patient Engagement in Research |
|
| SA-L3-C5-EN-V1 | Roles and Responsibilities in Clinical Research |
|
| SA-L3-C6-EN-V1 | Good Documentation Practices |
|
| SA-L3-C7-EN-V1 | Ethics and Informed Consent |
|
| SA-L3-C8-EN-V1 | Participant Recruitment |
|
| SA-L3-C9-EN-V1 | Participant Safety and Adverse Events |
|
| SA-L3-C10-EN-V1 | Data Management in Clinical Research |
|
| SA-L3-C11-EN-V1 | Study Oversight and Monitoring |
|
